Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters.

Hahn MK, Cohn T, Teo C, Remington G.

Clin Schizophr Relat Psychoses. 2013 Jan;6(4):186-96. doi: 10.3371/CSRP.HACO.01062013. Review.

PMID:
23302448
2.

Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects.

Hahn MK, Remington G, Bois D, Cohn T.

J Clin Psychopharmacol. 2010 Dec;30(6):706-10.

PMID:
21105286
3.

Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial.

Behdani F, Hebrani P, Rezaei Ardani A, Rafee E.

Arch Iran Med. 2011 Jul;14(4):270-5. doi: 0011144/AIM.009. Erratum in: Arch Iran Med. 2012 Aug;15(8):524.

4.

Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial.

Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, Talaei M.

J Psychopharmacol. 2009 Mar;23(2):157-62. doi: 10.1177/0269881108089816. Epub 2008 May 30.

PMID:
18515465
5.
6.

Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.

Muscatello MR, Bruno A, Pandolfo G, Micò U, Bellinghieri PM, Scimeca G, Cacciola M, Campolo D, Settineri S, Zoccali R.

J Psychopharmacol. 2011 May;25(5):667-74. doi: 10.1177/0269881110372548. Epub 2010 Jul 8.

PMID:
20615930
7.

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain.

Ko YH, Joe SH, Jung IK, Kim SH.

Clin Neuropharmacol. 2005 Jul-Aug;28(4):169-75.

PMID:
16062095
8.

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.

Ellinger LK, Ipema HJ, Stachnik JM.

Ann Pharmacother. 2010 Apr;44(4):668-79. doi: 10.1345/aph.1M550. Epub 2010 Mar 16. Review.

PMID:
20233913
9.

Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis.

Veerman SR, Schulte PF, Begemann MJ, Engelsbel F, de Haan L.

Pharmacopsychiatry. 2014 Sep;47(6):185-94. doi: 10.1055/s-0034-1383656. Epub 2014 Jul 7. Review.

PMID:
25002291
10.

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine.

Muscatello MR, Bruno A, De Fazio P, Segura-Garcia C, Pandolfo G, Zoccali R.

Expert Opin Pharmacother. 2014 Nov;15(16):2329-45. doi: 10.1517/14656566.2014.956082. Epub 2014 Oct 5. Review.

PMID:
25284216
11.
12.

Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.

Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvärinen S, Eronen M, Putkonen H, Takala P, Mehtonen OP, Puck M, Oksanen J, Koskelainen P, Joffe G, Aer J, Hallikainen T, Ryynänen OP, Tupala E.

J Clin Psychiatry. 2005 Aug;66(8):1012-5.

PMID:
16086616
13.

Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis.

Gobbi G, Gaudreau PO, Leblanc N.

J Clin Psychopharmacol. 2006 Oct;26(5):467-73.

PMID:
16974186
14.

Clozapine augmentation: safety and efficacy.

Chong SA, Remington G.

Schizophr Bull. 2000;26(2):421-40. Review.

PMID:
10885641
15.

Topiramate for clozapine-induced seizures.

Navarro V, Pons A, Romero A, Bernardo M.

Am J Psychiatry. 2001 Jun;158(6):968-9. No abstract available.

PMID:
11384919
16.

Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication.

Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI.

Clin Neuropharmacol. 2001 Sep-Oct;24(5):290-4.

PMID:
11586114
17.

Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.

Raskin S, Katz G, Zislin Z, Knobler HY, Durst R.

Acta Psychiatr Scand. 2000 Apr;101(4):334-6.

PMID:
10782556
18.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
20.

Metabolic side effects of antipsychotic medication.

Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF.

Int J Clin Pract. 2007 Aug;61(8):1356-70. Review.

PMID:
17627711

Supplemental Content

Support Center